HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Boyle, P. J. Articles by Freeman, J. S. Search for Related Content PubMed PubMed Citation Articles by Boyle, P. J. Articles by Freeman, J. S.

Dr Boyle is a professor of medicine at the University of New Mexico in Albuquerque, and Dr Freeman is chair and course director in the Division of Endocrinology at the Philadelphia College of Osteopathic Medicine in Philadelphia, Pa.

Address correspondence to Patrick J. Boyle, MD, Professor of Medicine, University of New Mexico, Albuquerque, NM 87131-0001. E-mail: pboyle{at}salud.unm.edu

Approximately two thirds of patients with type 2 diabetes mellitus (T2DM) are unable to reach the hemoglobin A_1c target set by the American Diabetes Association (HbA_1c <7.0%). Therefore, T2DM continues to be a major public health concern. Incretin mimetics and dipeptidyl peptidase IV inhibitors are medications that have the potential to improve patients' glycemic control, as well as to result in beneficial socioeconomic effects. Research suggests that significant benefits are to be gained from incretin mimetics and dipeptidyl peptidase IV inhibitors, either one used as monotherapy or used together as combination therapy. However, the benefits and risks of these agents need to be evaluated more thoroughly, with emphasis on such adverse effects as edema, hypoglycemia, and weight gain.